BrownellJ,PolyakSJ, 2013.Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer,Clin Cancer Res 19 1347 -52
KhaderiS,ShepherdR,GossJA,LeungDH, 2014.Hepatitis C in the pediatric population: transmission, natural history, treatment and liver transplantation,World J Gastroenterol 20 11281 -6
IslamMS,MiahMR,RoyPK,RahmanO,SiddiqueAB,ChowdhuryJ, 2015.Genotypes of hepatitis C virus infection in Bangladeshi population,Mymensingh Med J 24 143 -51
TahirA,MalikFR,AhmadI,KrishinJ,AkhtarP, 2011.Aetiological factors of chronic liver disease in children,J Ayub Med Coll Abottabad 23 12 -4
SokalEM,BourgoisA,StéphenneX,SilveiraT,PortaG,GardovskaD, 2010.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents,J Hepatol 52 827 -31
WirthS,Pieper-BoustaniH,LangT,BallauffA,KullmerU,GernerP, 2005.Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C,Hepatology 41 1013 -8
DruytsE,ThorlundK,WuP,KantersS,YayaS,CooperCL, 2013.Efficacy and safety of pegylated interferon alfa-2a or alfa2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and metaanalysis,Clin Infect Dis 56 961 -7
SchwarzKB,Gonzalez-PeraltaRP,MurrayKF,MollestonJP,HaberBA,JonasMM, 2011.The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C,Gastroenterology 140 450 -8
TomerY, 2010.Hepatitis C and interferon induced thyroiditis,J Autoimmun 34 J322 -6
De FranceschiL,FattovichG,TurriniF,AyiK,BrugnaraC,ManzatoF, 2000.Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage,Hepatology 31 997 -1004
HerbstDA,ReddyKR, 2013.Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection,Expert Opin Investig Drugs 22 527 -36
GaneEJ,StedmanCA,HylandRH,DingX,SvarovskaiaE,SymondsWT, 2013.Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C,N Engl J Med 368 34 -44
AzizS,RajperJ,NoorulainW., 2012.Treatment outcome of HCV infected paediatric patients and young adults at Karachi, Pakistan,J Ayub Med Coll Abbottabad 24 56 -8
El-ShabrawiMH,KamalNM, 2013.,World J Gastroenterol 19 7880 -8
MackCL,Gonzalez-PeraltaRP,GuptaN,LeungD,NarkewiczMR,RobertsEA,Nutrition., 2012.NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents,J Pediatr Gastroenterol Nutr 54 838 -55
WiegandJ,SchiefkeI,SteinK,BergT,KulligU,Ende K, 2016.Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders,Hamostaseologie 36 -
AlonsoS,Riveiro-BarcielaM,FernandezI,RincónD,RealY,LlerenaS, 2017.Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort,J Viral Hepat 24 304 -11
MehtaR,KabrawalaM,NandwaniS,TekriwalR,NandaniyaP,ShahM, 2016.Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort,Indian J Gastroenterol 35 459 -64
.Safety and efficacy of sofosbuvir + ribavirin in adolescents and children with genotype 2 or 3 chronic HCV infection, -
.Safety and efficacy of ledipasvir/sofosbuvir fixed dose combination +/- ribavirin in adolescents and children with chronic HCV-infection, -